GSK plc – Consensus ‘Hold’ rating and 22.7% Upside Potential

Broker Ratings

GSK plc which can be found using ticker (GSK) now have 4 market analysts covering the stock. The analyst consensus now points to a rating of ‘Hold’. The target price High/Low ranges between 63.75 and 35.5 calculating the mean target price we have $44.11. Given that the stocks previous close was at $35.95 and the analysts are correct then there would likely be a percentage uptick in value of 22.7%. The 50 day MA is $34.98 and the 200 day moving average is $35.27. The total market capitalization for the company now stands at $74,835m. You can visit the company’s website by visiting: https://www.gsk.com

The potential market cap would be $91,821m based on the market consensus.

GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom.

The company has a dividend yield of 4.12% with the ex dividend date set at 23-2-2023 (DMY).

Other points of data to note are a P/E ratio of 13.54, revenue per share of 14.57 and a 6.57% return on assets.

Share on:
Find more news, interviews, share price & company profile here for:

    GSK Plc completes acquisition of IDRx, Inc.

    GSK plc has completed its acquisition of IDRx, Inc., aiming to advance treatments for gastrointestinal stromal tumours with the novel IDRX-42 inhibitor.

    GSK Plc 5-in-1 meningococcal vaccine approved by FDA

    GSK's Penmenvy vaccine wins FDA approval, offering protection for ages 10-25 against five major meningococcal serogroups, aiming to boost vaccination rates.

    GSK Plc reports strong growth in Specialty Medicines and R&D progress

    GSK plc reports robust 2024 performance with strong Specialty Medicines growth, promising R&D advancements, and strategic shareholder returns.

    GSK plc Depemokimab applications accepted for review in China and Japan

    GSK's depemokimab, an ultra-long-acting biologic, is up for regulatory review in China and Japan for asthma and CRSwNP, based on positive trial results.

    GSK Plc Shingrix new prefilled syringe presentation accepted for review by EMA

    GSK's innovative prefilled Shingrix syringe gains EMA review, aiming to simplify shingles prevention for healthcare professionals across Europe.

    GSK’s Jemperli gains EU approval for advanced endometrial cancer treatment

    GSK's Jemperli plus chemotherapy gains EU approval for broader use in first-line treatment of advanced or recurrent endometrial cancer, improving survival rates.

      Search

      Search